NF-κB Activity Regulates Mesenchymal Stem Cell Accumulation at Tumor Sites

Abstract

Mesenchymal stem cells (MSC) accumulate at tumor sites when injected into tumor-bearing mice, perhaps offering cellular vectors for cancer-targeted gene therapy. However, the molecular mechanisms involved in MSC targeting the tumors are presently little understood. We focused on MSC-endothelial cell (EC) adhesion following TNF-a stimulation in an attempt to elucidate these mechanisms. Interestingly, stimulation of MSCs with TNF-a enhanced the adhesion of MSCs to endothelial cells in vitro. This adhesion was partially inhibited by blocking antibodies against vascular cell adhesion molecule-1 (VCAM-1) and very late antigen-4 (VLA-4). It is well known that TNF-a induces VCAM-1 expression via the NF-kB signaling pathway. Parthenolide has an anti-inflammatory activity and suppressed NF-kB activity by inhibition of IkBa phosphorylation after TNF-a stimulation and strongly inhibited TNF-a-induced VCAM-1 expression on MSCs. In vivo imaging using luciferase-expressing MSCs revealed that the bioluminescent signal gradually increased at tumor sites in mice injected with untreated MSCs. In contrast, we observed very weak signals at tumor sites in mice injected with parthenolide-treated MSCs. Our results suggest that NF-kB activity regulates MSC accumulation at tumors, by inducing VCAM-1 and thereby its interaction with tumor vessel endothelial cells. These findings have implications for the ongoing development of efficient MSC-based gene therapies for cancer treatment. Cancer Res; 73(1); 364-72. Ó2012 AACR.

Transcriptional Profiling Reveals Crosstalk Between Mesenchymal Stem Cells and Endothelial Cells Promoting Prevascularization by Reciprocal Mechanisms

“…NF-kB plays a key role in regulating a wide range of physiological processes, including inflammation, cancer progression, synaptic plasticity, and angiogenic response [52][53][54]. NF-kB may regulate the angiogenic potential and directional cell migration via stimulating adhesion molecules and cytokines, especially in tumor models and immune response [27,29,54,55]. In this work, we found NF-kB signaling was also involved in the prevascularization induced by ECs-MSCs coculture.…”

Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma

“…The increase in apoptosis seen in the intravenous delivery model could be a direct effect of the tumour receiving a greater number of cells and hence a higher dose of TRAIL. The first step in MSC accumulation within tumours is adhesion to vascular endothelial cells, and multiple factors are involved in this process 35 36. It may be that cells delivered intravenously have higher accumulation as they are delivered directly to endothelial cells, making adhesion more likely.…”

Systemic tumor-specific gene delivery

“…They are highly proliferative, easily isolated and can be genetically modified in culture to express genes that potentially could produce therapeutic effects. The excitement around MSCs as a gene delivery tool comes from the fact that they have been observed to accumulate in tumor tissue in a manner similar to how they migrate to any wound environment [47, 48]. The hope is that MSC's can be isolated, cultured, transfected with a therapeutic gene and administered systemically, whereupon they would migrate selectively to the tumor tissue and produce a therapeutic protein that would eliminate the tumor.…”